



09/663320
08-30-06

ccg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gavin C. Hirst et al.

Patent No.: 7,071,199

Date of Patent: July 4, 2006

Entitled: KINASE INHIBITORS AS
THERAPEUTIC AGENTS

Atty. Docket No.: BBC-081

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Certificate of Correction Branch

Certificate
SEP 01 2006
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 CFR 1.323

Sir/Madam:

Applicants request issuance of a certificate of correction in the above-cited patent. For this purpose, please find attached a form PTO/SB/44 (in duplicate), including at least one copy suitable for printing.

The errors in the patent are referred to below:

Column 98, line 33 – remove “;”

Column 99, line 29 – remove “,” before “thienyl”

Column 99, line 52 – add “,” after “quinazoline”

Column 102, line 12 – change “pyrimdinyI” to “pyrimidinyl”

Column 102, line 18 – add “,” after “N-oxides”

Column 102, line 30 – change “pyrimdinyI” to “pyrimidinyl”

Column 103, line 26 – change “pyrimdinyI” to “pyrimidinyl”

Column 105, line 38 – change “pyrimdinyI” to “pyrimidinyl”

Column 107, line 49 – change “pyrimdinyI” to “pyrimidinyl”

Column 109, line 3 – change “pyrimdinyI” to “pyrimidinyl”

Column 111, line 13 – change “pyrimdinyI” to “pyrimidinyl”

08/31/2006 MWOLDGE1 00000002 010025 7071199

01 FC:1811

100.00 DA


SEP 01 2006

- Column 112, line 43 – change “pyrimdiny” to “pyrimidiny”
- Column 114, line 17 – change “pyrimdiny” to “pyrimidiny”
- Column 116, line 6 – change “pyrimdiny” to “pyrimidiny”
- Column 117, line 31 – change “pyrimdiny” to “pyrimidiny”
- Column 119, line 2 – change “pyrimdiny” to “pyrimidiny”
- Column 119, lines 61-62 – delete “substituted or unsubstituted pyrazolyl,”
- Column 123, line 10 - delete “substituted or unsubstituted pyrazolylalkyl”
- Column 124, line 2 - delete “substituted or unsubstituted pyrazolylalkyl”
- Column 124, line 51 – change “pyrimdinyalkyl” to “pyrimidinyalkyl”
- Column 125, line 46-47 – delete “substituted or unsubstituted pyrazolyl,”
- Column 126, line 36 – change “benzthiazolyl” to “benzothiazolyl”
- Column 127, line 65 – delete “optionally substituted pyrazolylalkyl”
- Column 128, line 21-22 – change “(hydroxymethyl)piperdiny” to (hydroxymethyl)piperidiny”
- Column 130, line 44 – insert “(” before “straight”
- Column 130, line 47 – insert “-“ after “unsaturation)” and before “phenyl;”

It is respectfully requested that the issued Certificate of Correction be sent to the undersigned at the address listed below.


It is believed that the mistakes in the patent were made as a result of the fault of the Applicant. Pursuant to 37 CFR §1.20(a), a fee of \$100.00 is required with this submission and the Commissioner is hereby authorized to charge this fee and any other fee deficiencies connected with this or any accompanying paper to Applicants' Deposit Account.

Respectfully submitted,



Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
(508) 688-8053

SEP 01 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gavin C. Hirst et al.

Patent No.: 7,071,199

Date of Patent: July 4, 2006

Entitled: KINASE INHIBITORS AS
THERAPEUTIC AGENTS

Atty. Docket No.: BBC-81/A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Certificate of Correction Branch

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EQ651930845US, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

August 29, 2006
date of mailing and signature

Lisa Rasmussen
Lisa Rasmussen

TRANSMITTAL LETTER

Sir/Madam:

Transmitted herewith are: ☒ Request for Certificate of Correction pursuant to 37 CFR 1.323 (in duplicate); ☒ Form PTO/SB/44 (in duplicate); and ☒ An Acknowledgement Postcard to be filed in the above-identified patent application.

☒ The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 010025. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Gayle B. O'Brien

Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
(508) 688-8053

SEP 01 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Gavin C. Hirst et al.
Patent No.: 7,071,199
Date of Patent: July 4, 2006
Entitled: KINASE INHIBITORS AS
THERAPEUTIC AGENTS

Atty. Docket No.: BBC-81/A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Certificate of Correction Branch

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that the correspondence listed below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EQ651930845US**, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

August 29, 2006
date of mailing and signature

Lisa Rasmussen
Lisa Rasmussen

TRANSMITTAL LETTER

Sir/Madam:

Transmitted herewith are: [X] Request for Certificate of Correction pursuant to 37 CFR 1.323 (in duplicate); [X] Form PTO/SB/44 (in duplicate); and [X] An Acknowledgement Postcard to be filed in the above-identified patent application.

[X] **The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 010025. A duplicate copy of this transmittal letter is transmitted herewith.**

Respectfully submitted,

Gayle B. O'Brien

Gayle B. O'Brien
Agent for Applicants
Reg. No. 48,812
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605
(508) 688-8053

SEP 01 2006

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,071,199
APPLICATION NO.: 09/663,320
ISSUE DATE : July 4, 2006
INVENTOR(S) : Gavin C. Hirst et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 98, line 33 – remove “;”
Column 99, line 29 – remove “,” before “thienyl”
Column 99, line 52 – add “,” after “quinazoline”
Column 102, line 12 – change “pyrimdinyI” to “pyrimidinyl”
Column 102, line 18 – add “,” after “N-oxides”
Column 102, line 30 – change “pyrimdinyI” to “pyrimidinyl”
Column 103, line 26 – change “pyrimdinyI” to “pyrimidinyl”
Column 105, line 38 – change “pyrimdinyI” to “pyrimidinyl”
Column 107, line 49 – change “pyrimdinyI” to “pyrimidinyl”
Column 109, line 3 – change “pyrimdinyI” to “pyrimidinyl”
Column 111, line 13 – change “pyrimdinyI” to “pyrimidinyl”
Column 112, line 43 – change “pyrimdinyI” to “pyrimidinyl”
Column 114, line 17 – change “pyrimdinyI” to “pyrimidinyl”
Column 116, line 6 – change “pyrimdinyI” to “pyrimidinyl”
Column 117, line 31 – change “pyrimdinyI” to “pyrimidinyl”

MAILING ADDRESS OF SENDER (Please do not use customer number below):

100 Research Drive
Worcester, MA 01605-4314

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 01 2006

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 2 of 2

PATENT NO. : 7,071,199
APPLICATION NO.: 09/663,320
ISSUE DATE : July 4, 2006
INVENTOR(S) : Gavin C. Hirst et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 119, line 2 – change “pyrimdinyI” to “pyrimidinyl”
Column 119, lines 61-62 – delete “substituted or unsubstituted pyrazolyl,”
Column 123, line 10 - delete “substituted or unsubstituted pyrazolylalkyl”
Column 124, line 2 - delete “substituted or unsubstituted pyrazolylalkyl”
Column 124, line 51 – change “pyrimdinyIalkyl” to “pyrimidinylalkyl”
Column 125, line 46-47 – delete “substituted or unsubstituted pyrazolyl,”
Column 126, line 36 – change “benzthiazolyl” to “benzothiazolyl”
Column 127, line 65 – delete “optionally substituted pyrazolylalkyl”
Column 128, line 21-22 – change “(hydroxymethyl)piperdinyI” to
(hydroxymethylpiperidinyl”
Column 130, line 44 – insert “(” before “straight”
Column 130, line 47 – insert “-“ after “unsaturation)” and before “phenyl;”

MAILING ADDRESS OF SENDER (Please do not use customer number below):

100 Research Drive
Worcester, MA 01605-4314

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 01 2006

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,071,199
APPLICATION NO.: 09/663,320
ISSUE DATE : July 4, 2006
INVENTOR(S) : Gavin C. Hirst et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 98, line 33 – remove “;”
Column 99, line 29 – remove “,” before “thienyl”
Column 99, line 52 – add “,” after “quinazoline”
Column 102, line 12 – change “pyrimdinyI” to “pyrimidinyl”
Column 102, line 18 – add “,” after “N-oxides”
Column 102, line 30 – change “pyrimdinyI” to “pyrimidinyl”
Column 103, line 26 – change “pyrimdinyI” to “pyrimidinyl”
Column 105, line 38 – change “pyrimdinyI” to “pyrimidinyl”
Column 107, line 49 – change “pyrimdinyI” to “pyrimidinyl”
Column 109, line 3 – change “pyrimdinyI” to “pyrimidinyl”
Column 111, line 13 – change “pyrimdinyI” to “pyrimidinyl”
Column 112, line 43 – change “pyrimdinyI” to “pyrimidinyl”
Column 114, line 17 – change “pyrimdinyI” to “pyrimidinyl”
Column 116, line 6 – change “pyrimdinyI” to “pyrimidinyl”
Column 117, line 31 – change “pyrimdinyI” to “pyrimidinyl”

MAILING ADDRESS OF SENDER (Please do not use customer number below):

100 Research Drive
Worcester, MA 01605-4314

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 01 2006

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,071,199
APPLICATION NO.: 09/663,320
ISSUE DATE : July 4, 2006
INVENTOR(S) : Gavin C. Hirst et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 119, line 2 – change “pyrimdinyI” to “pyrimidinyl”
- Column 119, lines 61-62 – delete “substituted or unsubstituted pyrazolyl,”
- Column 123, line 10 - delete “substituted or unsubstituted pyrazolylalkyl”
- Column 124, line 2 - delete “substituted or unsubstituted pyrazolylalkyl”
- Column 124, line 51 – change “pyrimdinyIalkyl” to “pyrimidinylalkyl”
- Column 125, line 46-47 – delete “substituted or unsubstituted pyrazolyl,”
- Column 126, line 36 – change “benzthiazolyl” to “benzothiazolyl”
- Column 127, line 65 – delete “optionally substituted pyrazolylalkyl”
- Column 128, line 21-22 – change “(hydroxymethyl)piperdinyI” to “(hydroxymethyl)piperidinyl”
- Column 130, line 44 – insert “(” before “straight”
- Column 130, line 47 – insert “-“ after “unsaturation)” and before “phenyl;”

MAILING ADDRESS OF SENDER (Please do not use customer number below):

100 Research Drive
Worcester, MA 01605-4314

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 01 2006